Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice
Marino Paroli1, Rosalba Caccavale1, Daniele Accapezzato1
1Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy.
Cells
|February 9, 2024
Summary
Giant cell arteritis (GCA) is an inflammatory condition affecting older adults. Research explores its molecular and cellular mechanisms to find new diagnostic biomarkers and targeted therapies beyond glucocorticoids.
Area of Science:
- Immunology
- Rheumatology
- Pathology
Background:
- Giant cell arteritis (GCA) is a noninfectious granulomatous vasculitis primarily affecting individuals over 50.
- It presents in cranial (temporal arteritis) and extracranial forms, impacting large vessels like the aorta.
- Genetic predisposition and epigenetic factors contribute to GCA development.
Purpose of the Study:
- To review new insights into the molecular and cellular pathogenesis of GCA.
- To discuss implications for developing novel diagnostic biomarkers.
- To explore targeted therapies that could replace current glucocorticoid treatment.
Main Methods:
- Review of current literature on GCA pathogenesis.
- Analysis of molecular and cellular mechanisms involved in granuloma formation and vascular remodeling.
- Discussion of emerging diagnostic and therapeutic strategies.
Main Results:
- Innate and adaptive immune cells are crucial in forming granulomas and arterial tertiary lymphoid organs.
- Vessel wall cells, including VSMCs and endothelial cells, actively participate in vascular remodeling, leading to stenosis and ischemia.
- New understanding points towards potential biomarkers and targeted drug development.
Conclusions:
- Elucidating GCA's complex pathogenesis is key to advancing diagnostics and therapeutics.
- Targeted therapies hold promise for improved patient outcomes and reduced reliance on glucocorticoids.
- Further research into molecular and cellular pathways is essential for developing effective treatments.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:20COPD: Pathogenesis and Clinical Features
273
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
273
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166